Phase 1b Study of OMTX705 in Patients with Advanced/Metastatic Pancreatic Adenocarcinoma

The primary objective of the study titled "OMTX705-006 Phase 1b" is not explicitly stated. However, the study focuses on **Advanced/Metastatic Pancreatic Adenocarcinoma**, a condition characterized by the spread of cancerous cells from the pancreas to other parts of the body. Understanding the primary objective is crucial as it typically involves evaluating the safety, efficacy, or optimal dosing of a therapeutic intervention, which is vital for improving patient outcomes in this aggressive cancer type.

The clinical trial involves a total of **9 participants** diagnosed with **advanced/metastatic pancreatic adenocarcinoma**. The study population includes both male and female subjects, with an age range spanning from adults to the elderly. Participants were selected without targeting any vulnerable populations. The general health status of the participants is not specified, but they are likely to be affected by the aforementioned medical condition. No specific lifestyle considerations such as diet, physical activity, or habits are detailed in the available data. The sponsor has not provided information regarding the main objective of the trial or the principal inclusion criteria.

The clinical trial is designed to evaluate the efficacy and safety of an investigational treatment for **advanced/metastatic pancreatic adenocarcinoma**. This study is a Phase 3 trial, which is typically conducted to confirm the effectiveness of a treatment, monitor side effects, and collect information that will allow the treatment to be used safely. The trial is expected to commence recruitment on September 30, 2025, and is estimated to conclude by July 29, 2029. The study employs a randomized, double-blind, controlled design to ensure unbiased results and to compare the investigational treatment against a standard or placebo control.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. This visit will involve a comprehensive evaluation, including medical history, physical examination, and laboratory tests. Following successful screening, participants will be randomized to receive either the investigational treatment or a control. Subsequent follow-up visits will be scheduled at regular intervals to monitor the participants' health, assess treatment efficacy, and record any adverse events. These visits will include physical examinations, laboratory tests, and imaging studies as necessary. The end-of-study visit will occur after the final treatment cycle, where a thorough assessment will be conducted to evaluate the overall outcomes and any long-term effects of the treatment.

The expected length of participant involvement in the trial will vary depending on individual response to treatment and the overall study timeline. Participants may be withdrawn from the study early if they experience significant adverse effects, if the disease progresses despite treatment, or if they choose to withdraw consent. The trial is conducted in accordance with ethical guidelines and regulatory requirements to ensure the safety and well-being of all participants.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In addition to the experimental medication, the trial may include the use of **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatments. However, the data does not provide explicit details about these treatments. Information regarding the administration, dosing schedules, and participant compliance monitoring for these non-experimental treatments is also not available.

Due to the lack of specific information in the source data, further details about the **experimental medication** and any **non-experimental treatments** cannot be provided. The trial documentation should be consulted for comprehensive information regarding the treatments used in this clinical trial.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on September 30, 2025, with an estimated completion date of July 29, 2029. The efficacy assessment will be conducted through a series of pre-defined parameters, although specific endpoints are not detailed in the available data. The trial will follow a structured methodology to ensure the accurate collection and analysis of efficacy data, adhering to the rigorous standards expected in a Phase 3 clinical trial. The trial's design and execution will be aligned with the objective of evaluating the therapeutic impact of the investigational product, ensuring that all efficacy assessments are conducted systematically and consistently throughout the study duration.